#Ticagrelor versus Clopidogrel in Symptomatic Peripheral #Artery Disease

http://www.nejm.org/doi/full/10.1056/NEJMoa1611688?query=featured_home#abstract

In patients with symptomatic peripheral artery disease, ticagrelor was not shown to be superior to clopidogrel for the reduction of cardiovascular events. Major bleeding occurred at similar rates among the patients in the two trial groups.

Efficacy and safety of #ticagrelor versus aspirin in acute #stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial

http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(17)30038-8/abstract

randomly allocated patients (1:1) to ticagrelor (180 mg loading dose on day 1 followed by 90 mg twice daily for days 2–90, given orally) or aspirin (300 mg on day 1 followed by 100 mg daily for days 2–90, given orally) within 24 h of symptom onset.

In this prespecified exploratory analysis, ticagrelor was superior to aspirin at preventing stroke, myocardial infarction, or death at 90 days in patients with acute ischaemic stroke or transient ischaemic attack when associated with ipsilateral atherosclerotic stenosis. An understanding of stroke mechanisms and causes is important to deliver safe and efficacious treatments for early stroke prevention.

!!
#Antibacterial Activity of #Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria

https://jamanetwork.com/journals/jamacardiology/fullarticle/2732487

Ticagrelor reversibly inhibits the platelet adenosine diphosphate P2Y12 receptor (P2Y12).1 It is approved for prevention of cardiovascular events in patients with atherosclerotic cardiovascular disease and shows evidence of superior clinical performance compared with other P2Y12 inhibitors. A post hoc analysis of the Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome (PLATO) trial2 revealed that patients treated with ticagrelor had a lower risk of infection-related death than those treated with clopidogrel bisulfate.3 More recently, in the Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor (XANTHIPPE) study, ticagrelor was associated with improved lung function in patients hospitalized for pneumonia.

Ticagrelor and AR-C124910 had bactericidal activity against all gram-positive strains tested, including drug-resistant strains GISA, MRSE, MRSA, and VRE. The minimal bactericidal concentration was 20 μg/mL against MSSA, GISA, MRSA, and VRE; 30 μg/mL against MRSE; and 40 μg/mL against E faecalis and S agalactiae..

!!
#Ticagrelor with or without #Aspirin in High-Risk Patients after #PCI

https://www.nejm.org/doi/full/10.1056/NEJMoa1908419

Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary intervention (PCI).

..The difference in risk between the groups was similar for BARC type 3 or 5 bleeding (incidence, 1.0% among patients receiving ticagrelor plus placebo and 2.0% among patients receiving ticagrelor plus aspirin; hazard ratio, 0.49; 95% CI, 0.33 to 0.74). The incidence of death from any cause, nonfatal myocardial infarction, or nonfatal stroke was 3.9% in both groups (difference, −0.06 percentage points; 95% CI, −0.97 to 0.84; hazard ratio, 0.99; 95% CI, 0.78 to 1.25; P<0.001 for noninferiority).

CONCLUSIONS
Among high-risk patients who underwent PCI and completed 3 months of dual antiplatelet therapy, ticagrelor monotherapy was associated with a lower incidence of clinically relevant bleeding than ticagrelor plus aspirin, with no higher risk of death, myocardial infarction, or stroke

Age- and Weight-Adapted Dose of #Prasugrel Versus Standard Dose of #Ticagrelor in Patients With Acute #Coronary Syndromes
https://2medical.news/2020/07/24/age-and-weight-adapted-dose-of-prasugrel-versus-standard-dose-of-ticagrelor-in-patients-with-acute-coronary-syndromes/

The efficacy and safety of a reduced dose of prasugrel versus a standard dose of ticagrelor in elderly patients or those with a low body weight presenting with an acute coronary syndrome (ACS) are unknown.. ..The efficacy and safety of a reduced dose of prasugrel versus a standard dose of ticagrelor in elderly patients or those with a low body weight presenting with an acute …

#Ticagrelor Added to #Aspirin in Acute Ischemic #Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke A Randomized Clinical Trial
https://2medical.news/2020/11/11/ticagrelor-added-to-aspirin-in-acute-ischemic-stroke-or-transient-ischemic-attack-in-prevention-of-disabling-stroke-a-randomized-clinical-trial/

Reduction of subsequent disabling stroke is the main goal of preventive treatment in the acute setting after transient ischemic attack (TIA) or minor ischemic stroke.. ..Ticagrelor (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-30) or placebo within 24 hours of symptom onset. All patients received aspirin, 300 to 325 mg on day 1 followed by 75 to 100 …

#Ticagrelor Added to #Aspirin in Acute Ischemic #Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke A Randomized Clinical Trial
https://2medical.news/2021/02/15/ticagrelor-added-to-aspirin-in-acute-ischemic-stroke-or-transient-ischemic-attack-in-prevention-of-disabling-stroke-a-randomized-clinical-trial-2/

Reduction of subsequent disabling stroke is the main goal of preventive treatment in the acute setting after transient ischemic attack (TIA) or minor ischemic stroke. Objective To evaluate the superiority of ticagrelor added to aspirin in preventing disabling stroke and to understand the factors associated with recurrent disabling stroke. Design, Setting, and Participants The Acute Stroke or Transient Ischemic Attack Treated With Ticagrelor and Aspirin …